Answers are grounded in this paper and cite their sources.
On January 4, 1998, the world's first composite head and neck transplantation, including the complete larynx, thyroid gland, parathyroid glands, five tracheal rings, and 75% of the pharynx, was performed after extensive animal model testing (1, 2). To our knowledge, this effort represents the longest continuous survival of a first organ transplant, when an immunosuppressive regimen was used. This report presents a comprehensive 12-year review of the insights obtained through the treatment of this unique individual. IMMUNOSUPPRESSION AND REJECTION The patient experienced a first episode of chronic rejection 15 months postoperatively, which was addressed with intravenous steroids. Concerns regarding nephrotoxicity led to the substitution of tacrolimus for cyclosporine, resulting in long-term stabilization of creatinine levels (Fig. 1). Presently, he remains on 2 mg of tacrolimus twice daily, 10 mg of prednisone daily, and 500 mg of mycophenolate mofetil twice daily, despite requiring short-term alterations in dosing.FIGURE 1.: This graph demonstrates serum creatinine concentration during the course of the transplant. The trend line demonstrates a progressive improvement in renal function from 2000 to till present.A second episode of rejection occurred in 2003. Vocal production again declined over several days, and endoscopy demonstrated profound edema of his epiglottis and glottis. His serum level of tacrolimus was found to be low normal (Fig. 2), and a dose escalation and a rescue with intravenous solumedrol were initiated. Resolution was rapid and vocal performance normalized as measured by endoscopic videostroboscopy.FIGURE 2.: This graph delineates the serum levels of tacrolimus over the life of the transplant, starting with the initial therapy in 1999 until the present. The normal effective range for tacrolimus is 5 to 20 ng/mL.An isolated left true vocal fold edema developed 9 years posttransplantation, presumed to represent chronic rejection because of the appearance consistent with the previous rejection episodes and the failure to respond to long-term antibiotics. Followed by serial endoscopic examination, this remained stable with a normal contralateral fold, resulting in a voice with mild roughness and no breathiness. At 11 years posttransplantation, edema also developed in the opposite vocal fold, requiring solumedrol rescue. The bilateral vocal fold edema resolved, voicing again returned to near-normal. There have been no further episodes that might be interpreted as representing rejection. There has been concern for potential significant decreases in bone mineral density given the patient's dependence on long-term oral steroids. However, the patient has experienced a single significant test-to-test decrease in bone mineral density at one site on repeat testing (Table 1). Subsequent testing revealed no changes in bone mineral density at the lumbar spine and improvement in the values at the femoral neck, yielding an overall picture of bone mineral stability.TABLE 1: The bone mineral density (g/cm2) of the world's first complete pharyngolaryngeal transplant at the lumbar spine and the right femoral neckCurrently, laboratory assessment demonstrates that the patient is euthyroid with 80% of function derived from the donor gland. The patient enjoys normal deglutition without aspiration as determined by modified barium swallow evaluations. Voice quality 12 years posttransplantation remains near-normal with mild roughness and no breathiness with one octave pitch control, adequate for all his functional needs. DISCUSSION Until efforts at biomedical engineering are successful at developing suitable laryngeal replacements for laryngectomees dissatisfied with tracheal puncture, electrolarynges, or esophageal speech, laryngeal transplantation represents the only viable option for restoration of normal speech (3, 4). The concern of posttransplant malignancy has prompted the development of newer agents with both immunosuppressive efficacy and tumor suppressive properties, for example sirolimus, a member of the mammalian target of rapamycin family of immunosuppressives. Research in our laboratory demonstrated regression of soft tissue sarcoma in a mouse model, with subsequent studies demonstrating efficacy against a squamous cell carcinoma cell line in mice and rats. Most recently, we have tested treatment efficacy in a murine laryngeal transplantation model (5–9). These results corroborate the findings in the renal transplantation literature and support the hypothesis that laryngeal transplantation using a sirolimus-based regimen may be a treatment for laryngeal cancer (10–12). Much consideration has been given to closure of our patient's tracheostoma. As the patient's true vocal folds are fixed in the near-midline position, an adequate laryngeal airway would need to be created before tracheostoma closure. This could be achieved with a cordotomy with little sacrifice in vocal quality or with alternatives including reinnervation by the phrenic nerve or biomechanical laryngeal pacing devices (13). Nevertheless, the degree of laryngeal edema experienced by our patient during the rejection episodes is likely to have compromised his airway if any of these strategies had been used. At this time, we recommend a small, self- sustaining permanent tracheostoma capable of voluntary closure on phonation (14). Currently, with the data on the toxicity and efficacy of the newer immunosuppressives, and in particular with the results of the antiproliferative efficacy of the mammalian target of rapamycin inhibitors and pulsing regimens developed in our laboratory, we believe that laryngeal transplantation should be made available to patients with conventionally unrepairable laryngeal trauma, to those with bulky benign neoplasms of the larynx for which laryngectomy is the only option, to those with laryngeal malignancy after other organ transplantation, and to patients who are tumor free for 5 or more years after laryngectomy. P. Daniel Knott1 Douglas Hicks1 William Braun2 Marshall Strome3 1 Head and Neck Institute The Cleveland Clinic Cleveland, OH 2 Nephrology and Hypertension Institute The Cleveland Clinic Cleveland, OH 3 New York Head and Neck Institute New York, NY
No takes yet. Share an insight, caveat, or question.
Knott et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: